UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2024 OR ☐ Transition report pursuant to Section 13 of 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-23329 Charles & Colvard, Ltd. (Exact name of registrant as specified in its charter) North Carolina 56-1928817 (State or other jurisdict ...

FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2025 BLUE OWL CAPITAL CORPORATION (Exact name of Registrant as Specified in Its Charter) Maryland 814-01190 47-5402460 (State or Other Jurisdiction of Incorporation) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communicatio ...

Financial Performance - Net sales for the thirteen weeks ended February 23, 2025, were $2,841.0 million, a decrease of 6.3% compared to $3,032.9 million for the same period in 2024[8]. - Net income for the thirty-nine weeks ended February 23, 2025, was $896.5 million, down 2.9% from $914.9 million for the same period in 2024[8]. - Earnings per share (EPS) for the thirteen weeks ended February 23, 2025, were $0.30, a decline of 53.1% compared to $0.64 for the same period in 2024[8]. - Comprehensive income attributable to Conagra Brands, Inc. for the thirty-nine weeks ended February 23, 2025, was $889.0 million, compared to $915.1 million for the same period in 2024[11]. - Net income for the thirty-nine weeks ended February 23, 2025, was $896.5 million, down from $914.9 million for the same period in the previous year, representing a decrease of about 2.6%[16]. - Net income attributable to Conagra Brands, Inc. for the thirty-nine weeks ended February 23, 2025, was $466.8 million, compared to $284.5 million for the same period in the previous year, representing a year-over-year increase of 64%[87]. - The company reported a net income of $145.1 million for the thirteen weeks ended February 23, 2025, compared to $308.8 million in the same period last year, reflecting a decrease of 53.0%[106]. - Diluted earnings per share for Q3 fiscal 2025 was $0.30, down from $0.64 in Q3 fiscal 2024, reflecting lower net income[116]. Expenses and Costs - Selling, general and administrative expenses increased to $443.7 million for the thirteen weeks ended February 23, 2025, up 14.5% from $387.4 million in the same period in 2024[8]. - The cost of goods sold for the thirty-nine weeks ended February 23, 2025, was $6,534.7 million, a decrease of 1.2% from $6,616.5 million in the same period in 2024[8]. - Interest expense, net, for the thirty-nine weeks ended February 23, 2025, was $314.9 million, down from $325.8 million for the same period in 2024[8]. - The company recognized an impairment charge of $27.2 million in the Refrigerated & Frozen segment during Q3 fiscal 2025[97]. - The company incurred asset impairment charges of $121.3 million during the period, compared to $50.9 million in the previous year[16]. Assets and Liabilities - Total current assets decreased from $3,149.5 million to $2,965.6 million, a decline of approximately 5.8%[13]. - Total liabilities decreased from $12,351.0 million to $11,965.4 million, a reduction of about 3.1%[13]. - Cash and cash equivalents at the end of the period decreased to $49.4 million from $77.7 million, a decline of approximately 36.4%[16]. - Current liabilities increased to $4,303.7 million as of February 23, 2025, compared to $3,241.8 million as of May 26, 2024, an increase of 33.0%[13]. - Goodwill increased from $10,325.9 million as of May 26, 2024, to $10,499.8 million as of February 23, 2025, reflecting an acquisition of $176.2 million and a currency translation adjustment of $(2.3) million[51]. Acquisitions and Divestitures - The company acquired Sweetwood Smoke & Co. for $179.4 million, with $129.9 million classified as goodwill[24]. - The company completed the sale of its 51.8% ownership stake in Agro Tech Foods Limited for net proceeds of $76.8 million, recognizing a loss of $2.3 million on the sale[27]. - The company recognized a loss on divestitures of $27.2 million for the thirteen weeks ended February 23, 2025, compared to no loss in the same period in 2024[8]. Restructuring and Plans - The Conagra Restructuring Plan has incurred cumulative charges of $310.2 million, with $90.7 million recognized in the first three quarters of fiscal 2025[34]. - The company has approved a total of $345.9 million for the Conagra Restructuring Plan, with $90.1 million in cash charges and $255.8 million in non-cash charges recognized[34]. - The company initiated plans to sell businesses within its Grocery & Snacks, Refrigerated & Frozen, and International segments, recognizing an impairment charge of $27.2 million in the third quarter of fiscal 2025[30]. Cash Flow and Financing - The company reported net cash flows from operating activities of $1,346.2 million, compared to $1,531.3 million in the prior year, a decrease of approximately 12.1%[16]. - Cash used in investing activities amounted to $457.2 million in the first three quarters of fiscal 2025, compared to $295.6 million in the same period of fiscal 2024[165]. - Cash used in financing activities was $914.3 million in the first three quarters of fiscal 2025, down from $1.25 billion in fiscal 2024, reflecting long-term debt repayments of $274.8 million and cash dividends paid of $502.2 million[166]. - The company repaid $1.0 billion of its 4.30% senior notes on May 1, 2024, funded by an unsecured term loan and commercial paper[37]. Market and Economic Conditions - The company anticipates ongoing challenges related to inflation, supply chain issues, and changing consumer preferences impacting future performance[111]. - The company anticipates continued economic pressures on consumers, including high inflation and potential tariff increases, which may affect volumes[118].

Financial Performance - Total revenues for the three months ended February 23, 2025, were $35,154,000, a slight decrease of 1.5% compared to $35,704,000 for the same period in 2024[11] - Gross profit for the nine months ended February 23, 2025, was $26,316,000, representing an increase of 7.1% from $24,578,000 in the prior year[11] - Operating loss for the three months ended February 23, 2025, was $(9,029,000), compared to a loss of $(895,000) for the same period in 2024[11] - Net loss for the nine months ended February 23, 2025, was $(37,570,000), compared to a net income of $19,096,000 for the same period in 2024[12] - The company reported a basic loss per share of $(0.47) for the three months ended February 23, 2025, compared to earnings of $0.48 per share for the same period in 2024[12] - For the nine months ended February 23, 2025, Lifecore Biomedical reported a net loss of $37,570,000 compared to a net income of $19,096,000 for the same period in 2024[16] Cash and Liquidity - Cash and cash equivalents decreased to $5,417,000 as of February 23, 2025, down from $8,462,000 as of May 26, 2024[9] - The company reported cash and cash equivalents of $5,417,000 at the end of the period, down from $19,091,000 at the beginning of the period[16] - Cash flows from operating activities resulted in a net cash used of $5,553,000 for the nine months ended February 23, 2025, an improvement from $8,459,000 in the prior year[16] - The company believes its cash from operations and available credit will be sufficient to finance operational and capital requirements for at least the next twelve months[173] Assets and Liabilities - Total assets decreased to $237,693,000 as of February 23, 2025, from $253,960,000 as of May 26, 2024[9] - Total liabilities decreased to $190,267,000 as of February 23, 2025, compared to $200,058,000 as of May 26, 2024[9] - The company’s accumulated deficit increased to $(204,093,000) as of February 23, 2025, from $(166,523,000) as of May 26, 2024[9] - The balance of redeemable convertible preferred stock increased to $45,197,000 as of February 23, 2025, from $44,312,000 at the end of the previous reporting period[16] Expenses - Research and development expenses for the three months ended February 23, 2025, were $2,045,000, a decrease of 5.8% from $2,170,000 in the same period last year[11] - Stock-based compensation increased to $8,343,000 in the nine months ended February 23, 2025, compared to $4,603,000 in the same period of 2024[16] - Total operating expenses for the nine months increased by 37% to $48,888 million, driven by a significant rise in selling, general, and administrative expenses[157] - Operating expenses increased by 48% to $18.874 million for the three months ended February 23, 2025, compared to $12.789 million for the same period in 2024[141] Debt and Financing - As of February 23, 2025, total debt net of discounts was $124,939 million, slightly up from $124,668 million on May 26, 2024[64] - The Company’s term loan principal is $184,361 million, with a significant portion due in 2029 amounting to $170,325 million[64] - The Term Loan Credit Facility has an effective annual interest rate of 20.9% as of February 23, 2025[69] - The Company incurred total expenses of $18,490 million under the restructuring plan, with expected remaining costs of $1,971 million, leading to total expected costs of $16,519 million[48] Revenue Concentration - The Company had significant revenue concentrations during the three months ended February 23, 2025, with two customers accounting for 54% and 18% of total revenues, compared to 52% and 14% in the same period of 2024[89] - Alcon accounted for 43% of the Company's revenues for the nine months ended February 23, 2025, highlighting its significance as a major customer[117] Stock and Equity - Lifecore Biomedical issued common stock, net of fees, amounting to $23,858,000 during the nine months ended February 23, 2025[16] - The Company issued 5,928,775 shares of common stock on October 3, 2024, for gross proceeds of approximately $24,300, with an issuance cost of $467[78] - As of February 23, 2025, the aggregate liquidation preference of the Redeemable Convertible Preferred Stock was $45,455, with $561 of dividends in arrears[80] Operational Highlights - Lifecore's vertically integrated capabilities allow for rapid movement from product development to commercial production, enhancing supply chain efficiency[132] - The FDA completed a GMP inspection of Lifecore in May 2025, with an initial response to observations provided within the expected timeframe[128] - The company has made strategic capital investments to extend its formulation and filling capacity to meet increasing partner demand[131] Compliance and Governance - Certifications of the Principal Executive Officer and Principal Financial Officer were filed pursuant to the Sarbanes-Oxley Act of 2002, ensuring compliance with regulatory requirements[192] - Management is committed to remediating material weaknesses in internal control over financial reporting, including engaging a third-party consultant and enhancing the internal audit function[180]

Financial Performance - NIKE, Inc. revenues for Q3 fiscal 2025 were $11.3 billion, a decrease of 9% compared to $12.4 billion in Q3 fiscal 2024[90]. - Net income for Q3 fiscal 2025 was $794 million, a decline of 32% from $1.172 billion in Q3 fiscal 2024[95]. - Earnings before interest and taxes (EBIT) for Q3 fiscal 2025 was $826 million, down 39% from $1.352 billion in Q3 fiscal 2024[93]. - For the first nine months of FY2025, NIKE, Inc. revenues totaled $35.2 billion, an 8% decrease from $38.8 billion in the same period of FY2024[101]. - Total revenues for the three months ended February 28, 2025, decreased by 4% to $4,864 million compared to $5,070 million in the same period last year[118]. - Total NIKE Brand EBIT decreased by 41% to $1,257 million for the three months ended February 28, 2025, compared to $2,128 million in the prior year[117]. - Reported EBIT decreased 26%, reflecting lower revenues and increased selling and administrative expenses driven by higher demand creation expenses[132]. Revenue Breakdown - NIKE Direct revenues were $4.7 billion for Q3 fiscal 2025, down 12% from $5.4 billion in Q3 fiscal 2024, representing approximately 43% of total NIKE Brand revenues[90]. - NIKE Brand revenues, accounting for over 90% of total revenues, decreased 9% on a reported basis and 6% on a currency-neutral basis, driven by declines in the Jordan Brand, Men's, Kids', and Women's categories[98]. - NIKE Brand wholesale revenues decreased 7% on a reported basis and 4% on a currency-neutral basis, impacted by lower revenues in Greater China, EMEA, and Asia Pacific & Latin America[98]. - NIKE Direct revenues were $4.7 billion in Q3 FY2025, down 10% from $5.4 billion in Q3 FY2024, primarily due to a 15% decline in NIKE Brand Digital sales[99]. - Greater China revenues decreased by 17% to $1,733 million for the three months ended February 28, 2025, compared to $2,084 million in the same period last year[128]. - APLA revenues decreased 4% on a currency-neutral basis, primarily due to lower revenues in Southeast Asia and India, with NIKE Direct revenues down 4% due to digital sales declines of 8%[135]. - Converse revenues decreased 16% on a currency-neutral basis, driven by revenue declines in all territories, with unit sales down 10% and ASP down 6% due to higher discounts[142]. Cost and Margin Analysis - Gross margin for Q3 fiscal 2025 decreased by 330 basis points to 41.5%, compared to 44.8% in Q3 fiscal 2024[90]. - Gross profit for Q3 FY2025 was $4.675 billion, a 16% decrease from $5.562 billion in Q3 FY2024, with a gross margin of 41.5%, down 330 basis points year-over-year[100]. - Gross margin contracted by 210 basis points primarily due to lower ASP and higher inventory obsolescence reserves[122]. - Gross margin contraction of approximately 470 basis points for Converse, primarily due to lower ASP, partially offset by lower product costs[142]. - The effective tax rate for Q3 FY2025 was 5.9%, a significant decrease from 16.5% in Q3 FY2024, primarily due to a one-time, non-cash deferred tax benefit[111]. Expenses and Investments - Demand creation expense increased by 8% to $1.088 billion in Q3 fiscal 2025, compared to $1.011 billion in Q3 fiscal 2024[95]. - Total selling and administrative expenses for Q3 FY2025 were $3.887 billion, an 8% decrease from $4.226 billion in Q3 FY2024, with demand creation expenses increasing by 8%[103]. - Selling and administrative expenses increased by 12% driven by higher operating overhead and demand creation expenses[122]. - Cash provided by operations was $3,235 million for the first nine months of fiscal 2025, down from $4,810 million for the same period in fiscal 2024[156]. - Cash used by investing activities was an outflow of $289 million for the first nine months of fiscal 2025, compared to an inflow of $1,184 million for the same period in fiscal 2024[157]. - Cash used by financing activities was an outflow of $4,176 million for the first nine months of fiscal 2025, a decrease from $4,468 million in the same period of fiscal 2024[158]. Shareholder Returns - NIKE returned approximately $1.1 billion to shareholders in Q3 fiscal 2025 through dividends and share repurchases[90]. - The company repurchased 34.4 million shares for $2,753 million at an average price of $80.02 per share under the $18 billion share repurchase plan[159]. Market Conditions and Risks - External factors such as geopolitical dynamics and fluctuating foreign exchange rates are creating uncertainty and volatility in the operating environment[88]. - The impact of foreign exchange rate fluctuations on consolidated revenues was a detriment of approximately $310 million for the three months ended February 28, 2025[153]. - The company has not experienced difficulty accessing capital or credit markets in fiscal 2025, although future volatility may increase costs[165]. - There have been no material changes in market risk disclosures compared to the previous Annual Report[174]. Strategic Initiatives - NIKE plans to reduce the supply of certain footwear products while shifting focus to new and innovative products[91]. - The company is repositioning NIKE Brand Digital as a full-price platform and reinvesting in wholesale distribution[91].

Revenue Performance - Revenues for Q4 FY 2025 increased to $932 million, up 5% in U.S. dollars and 9% in constant currency[2] - Full fiscal year 2025 revenues reached $3.0 billion, an 8% increase in U.S. dollars and a 10% increase in constant currency[20] - The Company's outlook for consolidated net revenue in fiscal 2026 is expected to increase between 3.9% and 6.2%[28] - Total net revenue for the three months ended February 1, 2025, was $932,252,000, representing a 5% increase from $891,050,000 in the prior year[57] - Total net revenue for the fiscal year ended February 1, 2025, reached $3,067,059 thousand, an 8% increase from $2,776,530 thousand in the previous fiscal year[60] Earnings and Profitability - GAAP EPS for Q4 FY 2025 was $1.16, a 32% decrease from $1.71 in the prior year[9] - Adjusted EPS for Q4 FY 2025 was $1.48, down 26% from $2.01 in the same prior-year quarter[10] - GAAP diluted EPS for fiscal 2026 is projected to be between $1.03 and $1.37, while adjusted diluted EPS is expected to range from $1.32 to $1.76[28] - Adjusted net earnings per diluted share for the three months ended February 1, 2025, were $1.48, compared to $2.01 for the same period last year[50] - Reported GAAP net earnings attributable to Guess?, Inc. for the three months ended February 1, 2025, were $81,399,000, a decrease of 29% compared to $115,270,000 for the same period last year[52] Operating Margins - GAAP operating margin for FY 2025 decreased to 5.8%, down from 9.5% in FY 2024[21] - The operating margin for the Company's Europe segment decreased by 2.1% to 9.5% in fiscal 2025, down from 11.6% in fiscal 2024, mainly due to higher expenses and unfavorable currency impacts[26] - The Americas Retail segment's operating margin fell by 7.0% to 1.0% in fiscal 2025, compared to 8.0% in fiscal 2024, driven by negative retail comparable sales and increased expenses[26] Expenses and Costs - Selling, general and administrative expenses increased to $1,134,643 thousand, representing 37.9% of net revenue for the fiscal year ended February 1, 2025, up from 34.4% in the previous year[49] - Adjusted selling, general and administrative expenses for the fiscal year ended February 1, 2025, were $1,121,044,000, up from $967,546,000 in the prior year, marking an increase of 15.8%[52] - Other expense, net for fiscal 2025 was $73.4 million, a significant increase from $5.1 million in fiscal 2024, primarily due to a net unrealized loss of $60.7 million related to derivatives[25] Cash Flow and Capital Management - The Company anticipates free cash flow of $55 million for fiscal 2026, with net cash provided by operating activities at $125 million[32] - Free cash flow for the fiscal year ended February 1, 2025, was $29,761 thousand, down from $248,422 thousand in the previous year[67] - The Company repurchased approximately 2.6 million shares for $60.3 million during fiscal 2025, leaving a capacity of $139.8 million under the share repurchase program[34] Store Operations and Acquisitions - The Company operates 1,070 retail stores directly and has partners operating an additional 527 stores worldwide as of February 1, 2025[41] - The company operated a total of 1,597 stores as of February 1, 2025, an increase from 1,553 stores as of February 3, 2024[69] - The acquisition of rag & bone contributed to revenue growth and was a significant milestone for the company[5] - The Company acquired all operating assets and a 50% interest in the intellectual property assets of rag & bone on April 2, 2024, enhancing its market presence[41] Tax and Other Financial Metrics - The effective income tax rate for the fiscal year ended February 1, 2025, was 12.0%, compared to 10.8% in the previous year[49] - The adjusted effective income tax rate for the fiscal year ended February 1, 2025, was 24.0%, compared to 22.2% in the previous year[52] - Total assets increased to $2,766,678 thousand as of February 1, 2025, from $2,590,021 thousand a year earlier[62] - Long-term debt and finance lease obligations rose to $150,668 thousand from $28,210 thousand year-over-year[62]

Financial Guidance - Full-year 2025 adjusted diluted EPS guidance is projected to be between $11.99 and $12.19, including the impact of Q1 2025 expenses[6] - Q1 2025 adjusted diluted EPS guidance is estimated to be between $2.34 and $2.38, factoring in the acquired IPR&D and milestones expense[6] Expenses and Impact - AbbVie expects acquired IPR&D and milestones expense of $248 million for Q1 2025, impacting GAAP and adjusted non-GAAP diluted EPS by $0.13[5] - The licensing agreement with Gubra for GUB014295 closed after Q1 2025 and is not included in the current guidance[6] Risks and Uncertainties - AbbVie cautions that forward-looking statements are subject to risks and uncertainties that may materially affect actual results[9]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 FIVE9, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) u ...

Financial Results - Emeren Group Ltd. announced preliminary financial results for Q1 2025 on March 28, 2025[6]. - The press release detailing financial results is included as Exhibit 99.1[15]. Leadership Changes - Mr. Yumin Liu will step down as CEO effective April 30, 2025, after over five years in the role[8][9]. - Ms. Julia Xu has been appointed as Interim CEO starting May 1, 2025, with a fee of $60,000 for the initial four-month term[10][11]. Strategic Initiatives - The Company received a going-private proposal on March 17, 2025, and formed a Special Committee to evaluate it[13]. - The Company is focusing on high-margin growth and capital-efficient development strategies[9]. Risk Factors - Forward-looking statements indicate potential risks including changes in market conditions and execution of strategic plans[14].

Financial Performance - Operating revenues for the three months ended February 28, 2025, increased to $187,064, representing a 23.4% growth compared to $151,519 for the same period in 2024[7] - Gross profit for the six months ended February 28, 2025, rose to $112,454, up 13.7% from $98,859 in the prior year[7] - Net earnings for the three months ended February 28, 2025, were $26,576, a 46.6% increase from $18,123 in the same quarter of 2024[8] - Earnings per share (EPS) for the six months ended February 28, 2025, increased to $4.03, compared to $3.01 for the same period in 2024, reflecting a 33.9% growth[7] - Operating income for the six months ended February 28, 2025, was $53,006, a 22.7% increase from $43,172 in the prior year[7] - Net earnings for the six months ended February 28, 2025, were $43,739 thousand, an increase from $33,142 thousand for the same period in the previous year, representing a growth of approximately 32.5%[16] - Total comprehensive income for the six months ended February 28, 2025, was $41,246 thousand, compared to $32,527 thousand for the same period in the prior year, indicating an increase of about 27.5%[16] Assets and Liabilities - Total assets as of February 28, 2025, amounted to $814,185, an increase from $765,280 as of February 29, 2024[10] - Total liabilities as of February 28, 2025, were $297,766, up from $282,246 as of February 29, 2024[10] - Cash and cash equivalents increased to $172,044 as of February 28, 2025, compared to $133,415 a year earlier, marking a 29% increase[10] - The total shareholders' equity as of February 28, 2025, was $516,419 thousand, an increase from $483,034 thousand as of February 29, 2024[14] - The company reported contract liabilities of $24.4 million as of February 28, 2025, up from $18.3 million as of February 29, 2024, representing a 33.3% increase[28] Cash Flow and Dividends - The company reported a net cash provided by operating activities of $33,880 thousand for the six months ended February 28, 2025, significantly higher than $12,136 thousand for the same period in the previous year[16] - Cash dividends paid were $7,824 thousand for the six months ended February 28, 2025, reflecting an increase from $7,724 thousand in the same period last year[16] - The Company declared cash dividends of $0.36 per share for the three months ended February 28, 2025, compared to $0.35 for the same period in 2024[7] Segment Performance - Irrigation segment revenues increased 11% to $148.1 million, while infrastructure segment revenues surged 110% to $38.9 million[68] - The irrigation segment accounted for 79% of the Company's revenue for the three months ended February 28, 2025, down from 88% in the prior year[77] - Segment operating income for the infrastructure segment increased 278% to $13.3 million, compared to $3.5 million in the prior year[76] Market and Economic Conditions - The U.S. Department of Agriculture forecasts 2025 U.S. net farm income to be $180.1 billion, a 29% increase from 2024[70] - The infrastructure business is expected to benefit from the $110 billion federal funding introduced by the Infrastructure Investment and Jobs Act, which runs through September 2026[73] Shareholder Actions - The company repurchased common stock worth $1,427 thousand during the six months ended February 28, 2025, compared to no repurchases in the same period last year[16] - The Company repurchased approximately 12,000 shares of its common stock for $1.4 million during the three and six months ended February 28, 2025, with $40.0 million remaining available for future repurchases[57] Tax and Compliance - The estimated annual effective income tax rate decreased to 20.9% for the six months ended February 28, 2025, down from 26.4% for the same period in 2024[35] - The Company was in compliance with all financial loan covenants as of February 28, 2025, and February 29, 2024[108] Environmental and Legal Matters - The Company has accrued an estimated environmental remediation liability of $10.6 million for its Lindsay, Nebraska facility, with $8.0 million calculated on a discounted basis[50] - The Company does not expect the ongoing product liability lawsuits related to its X-Lite® end terminal to have a material adverse effect on its business[49]